BridgeBio Pharma Cost of Goods Sold 2018-2024 | BBIO

BridgeBio Pharma cost of goods sold from 2018 to 2024. Cost of goods sold can be defined as the difference between beginning and ending inventories for tangible products resulting in an expense that reflects production and sales costs.
BridgeBio Pharma Annual Cost of Goods Sold
(Millions of US $)
2023 $2
2022 $3
2021 $3
2020 $
2019 $3
2018 $
2017 $
BridgeBio Pharma Quarterly Cost of Goods Sold
(Millions of US $)
2024-09-30 $1
2024-06-30 $1
2024-03-31 $1
2023-12-31 $1
2023-09-30 $1
2023-06-30 $1
2023-03-31 $1
2022-12-31 $1
2022-09-30 $1
2022-06-30 $1
2022-03-31 $1
2021-12-31 $2
2021-09-30 $1
2021-06-30 $0
2021-03-31
2020-12-31
2020-09-30
2020-06-30
2020-03-31
2019-12-31
2019-09-30 $3
2019-06-30
2019-03-31
2018-12-31
2018-09-30
2017-12-31
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $4.260B $0.009B
BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United States.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.044B 6.25
Dr Reddy's Laboratories (RDY) India $11.978B 22.92
Bausch Health Cos (BHC) Canada $3.012B 2.18
Amphastar Pharmaceuticals (AMPH) United States $2.097B 12.61
Supernus Pharmaceuticals (SUPN) United States $1.962B 26.71
Taysha Gene Therapies (TSHA) United States $0.434B 30.29
Personalis (PSNL) United States $0.261B 0.00
Assembly Biosciences (ASMB) United States $0.098B 0.00
Sol-Gel Technologies (SLGL) Israel $0.012B 0.00
Evoke Pharma (EVOK) United States $0.007B 0.00
Teligent (TLGT) United States $0.000B 0.00